IHME

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023
Janus, Partnership, RA, Astellas Pharma, Prevalence, JAK, Disease, GBD, Menarini, Inflammation, Institute for Health Metrics and Evaluation, Person, Pain, Patient, Rheumatoid arthritis, Joint, Diagnosis, Castleman Disease Collaborative Network, IHME, Pharmaceutical industry, Tablet

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023
Janus, Partnership, RA, Astellas Pharma, Prevalence, JAK, Disease, GBD, Menarini, Inflammation, Institute for Health Metrics and Evaluation, Person, Pain, Patient, Rheumatoid arthritis, Joint, Diagnosis, Castleman Disease Collaborative Network, IHME, Pharmaceutical industry, Tablet

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Study Finds Significantly More Adults Living with Diabetic Retinopathy in the United States than Previously Estimated

Retrieved on: 
Friday, June 16, 2023
Retina, Microsoft PowerPoint, University, Prevalence, Diabetes, Education, Visual impairment, Diabetic retinopathy, Centers for Disease Control and Prevention, Public, Policy, Eye, DR, Brain, Cell, Social media, Person, CDC, Vision, Ophthalmology, Institute for Health Metrics and Evaluation, Public health, NORC, Patient, Bleeding, Risk, University of Washington Department of Global Health, NORC at the University of Chicago, Mortality, Paratriathlon, MPH, White, IHME, Safety, Pharmaceutical industry, Medical device, Nursing, Soft drink, Toy, Dietary supplement, Doctor of Philosophy, JAMA Ophthalmology

CHICAGO, June 16, 2023 /PRNewswire-PRWeb/ --  A new study published today in JAMA Ophthalmology, "Prevalence of Diabetic Retinopathy in the US in 2021," found that in 2021, an estimated 9.6 million people in the United States (26.4 percent of those with diabetes) had diabetic retinopathy (DR), and 1.84 million people (5.1 percent of those with diabetes) had vision-threatening diabetic retinopathy (VTDR). The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004. VTDR has also almost doubled since last estimated in 2004.

Key Points: 
  • New study finds that nearly 10 million people in the US with diabetes have diabetic retinopathy.
  • The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004.
  • The study is the first of its kind to estimate the prevalence of DR and VTDR in people younger than 40 years.
  • For more information on the "The Prevalence of Diabetic Retinopathy in the United States In 2021" study or the VEHSS, visit https://www.cdc.gov/visionhealth/vehss/ .

Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting

Retrieved on: 
Monday, April 24, 2023
Mental Health, Health, Telemedicine, Virtual Medicine, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, DSM-IV codes, Spinal muscular atrophy, Survival, Multiple sclerosis, Science, Patient, Nervous system, Ageing, Policy, IHME, Disease, Maintenance, Cleveland Clinic, University, Disability, Cardiovascular disease, Dementia, Brain, NMOSD, Research, Satralizumab, RO, RMS, RRMS, Cleveland, Immunodeficiency, Phase, Death, Safety, Huntington's disease, Abstract, Natural history, COVID-19, Multimedia, ROG, Brainpower, Neuroscience, Myasthenia gravis, Cancer, EMPOWER, Angelman syndrome, SMA, Experience, Telehealth, Partnership, Central nervous system, AAN, American Academy, Digital technology, Annual general meeting, Neuromyelitis optica spectrum disorder, Tenecteplase, AD, Pharmaceutical industry, Medical imaging, Risdiplam, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is announcing three new partnerships focused on improving brain health outcomes.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is announcing three new partnerships focused on improving brain health outcomes.
  • “With that in mind, we are committed to developing and delivering new medicines that address areas of highest need in neuroscience.
  • See AAN oral presentation details on Genentech’s telehealth pilot with Cleveland Clinic here , Tuesday, April 25 at 3:54 p.m.
  • To meet the needs of people living with brain health conditions, Genentech is continuing to grow and advance its pipeline, with key areas of focus in neuroimmunologic, neuromuscular, neurodegenerative and neurodevelopmental diseases.

Atlanta Neuroscience Foundation Marks World Neuroscience Day with Keynote Speaker Mark Richt, Former UGA Football Coach

Retrieved on: 
Tuesday, April 18, 2023
Hyatt, Optimism, Education, Culture, AAN, Roche, Health equity, Health, Quality of life, Hope, American Academy, Microsoft, UGA, Parkinson's Foundation, Research, DSM-IV codes, Life expectancy, Parkinson, MS, Alzheimer's disease, Institute for Health Metrics and Evaluation, Parkinson's disease, Epilepsy Foundation, Gates Ventures, Diagnosis, American Academy of Neurology, ANF, IHME, Past // Present // Future, Caregiver, Pharmaceutical industry, Nursing, Epilepsy

ATLANTA, April 18, 2023 /PRNewswire/ -- Mark Richt, former UGA football coach, will be the keynote speaker and open the conference with a conversation highlighting his journey living with Parkinson's.

Key Points: 
  • ATLANTA, April 18, 2023 /PRNewswire/ -- Mark Richt, former UGA football coach, will be the keynote speaker and open the conference with a conversation highlighting his journey living with Parkinson's.
  • Following the opening general assembly, attendees will have access to neurology specialists addressing medical advancements, research, education, and patient outcomes.
  • World Neuroscience Day is an awareness campaign and conference created by the Atlanta Neuroscience Foundation (ANF), an Atlanta-based 501c3.
  • World Neuroscience Day conference will be held Saturday, May 6, 2023, at Grand Hyatt Hotel-Buckhead from 8:00 am to 4:00 pm.

New study reveals half of malnutrition-related deaths in those with clefts could be prevented

Retrieved on: 
Friday, October 7, 2022
Medical school, Risk, Disease, Organization, IHME, Mortality, Institute for Health Metrics and Evaluation, Institute, Death, University, University of Washington Department of Global Health, Malnutrition, Smile, MD, CEO, Cleft lip and cleft palate, Child, Hearing, Development, School, Dentistry, Birth control, Medicine

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- In a new report released today, World Smile Day, Smile Train and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington's School of Medicine find that nearly half of cleft-related malnutrition deaths globally in children under 5 could be prevented with access to adequate nutrition and surgical treatment.

Key Points: 
  • The report provides a first-of-its-kind look at the devastating impact of orofacial clefts over two decades, 2000 to 2020.
  • The report synthesized two sets of data, one from Smile Train Express and the other IHME's Global Burden of Disease Modeling demographic group.
  • If children with clefts did not experience higher rates of undernutrition, as many as 21,000 deaths worldwide could be averted with intervention.
  • Over the past 20 years, the number of children born with clefts under the age of 5 has failed to decline significantly.

New study reveals half of malnutrition-related deaths in those with clefts could be prevented

Retrieved on: 
Friday, October 7, 2022
Medical school, Risk, Disease, Organization, IHME, Mortality, Institute for Health Metrics and Evaluation, Institute, Death, University, University of Washington Department of Global Health, Malnutrition, Smile, MD, CEO, Cleft lip and cleft palate, Child, Hearing, Development, School, Dentistry, Birth control, Medicine

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- In a new report released today, World Smile Day, Smile Train and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington's School of Medicine find that nearly half of cleft-related malnutrition deaths globally in children under 5 could be prevented with access to adequate nutrition and surgical treatment.

Key Points: 
  • The report provides a first-of-its-kind look at the devastating impact of orofacial clefts over two decades, 2000 to 2020.
  • The report synthesized two sets of data, one from Smile Train Express and the other IHME's Global Burden of Disease Modeling demographic group.
  • If children with clefts did not experience higher rates of undernutrition, as many as 21,000 deaths worldwide could be averted with intervention.
  • Over the past 20 years, the number of children born with clefts under the age of 5 has failed to decline significantly.

IHME study shows dramatic variation in health care spending across US states

Retrieved on: 
Monday, August 1, 2022
Health care, University of Washington School of Medicine, Arizonan, Health insurance coverage in the United States, University, Fortis Healthcare, School, Hospital, Institute for Health Metrics and Evaluation, Research, Associate, Health, Institute, Income, University of Washington Department of Global Health, Multimedia, Indian Health Service, Affordable Care Act, Pregnancy, Veterans' affairs, Health Affairs, Department, IHME, Overalls, Medical school, Growth, Population, Health policy, Health insurance, Medicaid, Medicine, Medicare

SEATTLE, Aug. 1, 2022 /PRNewswire/ -- A new state-level analysis of health care costs after implementation of the Affordable Care Act shows wide variations in system-wide health care spending across states. The study, conducted by researchers from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington's School of Medicine and published today in the journal Health Affairs, reveals that differences in spending between states have increased over time, suggesting that some states are more effective at controlling rising health care costs than others. IHME's analysis also sheds light on the spending changes associated with Medicaid expansion on health care spending.

Key Points: 
  • SEATTLE, Aug. 1, 2022 /PRNewswire/ -- A new state-level analysis of health care costs after implementation of the Affordable Care Act shows wide variations in system-wide health care spending across states.
  • "Policymakers in states with higher health care costs can learn a lot from other states that deliver high-quality health care more efficiently."
  • "To help curb increases to health care spending, states should invest in delivering health care outside of hospitals through robust primary care systems and focus on incentivizing high-value care."
  • Because of data limitations, most previous studies of state-level health spending have looked at health care spending through 2014, prior to Medicaid expansion in states.

Mukteshwari "Mukti" Bosco Receives 2022 Roux Prize

Retrieved on: 
Friday, July 22, 2022
Indian Institute of Science, University of Washington School of Medicine, University, Health education, Woman, CEO, Institute for Health Metrics and Evaluation, Research, Disease, Population health, Health, Institute, Tata Institute of Social Sciences, Income, Deloitte, University of Washington Department of Global Health, Volunteering, Multimedia, Organization, Leadership, Government, Empowerment, Social science, CHE, IHME, Degenerative disease, Founder, Population, Health policy, Pharmaceutical industry, Medicine

SEATTLE, July 22, 2022 /PRNewswire/ -- The Institute for Health Metrics and Evaluation (IHME) at the University of Washington today announced Mukteshwari "Mukti" Bosco, CEO and Founder of Healing Fields Foundation, is the recipient of the 2022 Roux Prize, the world's largest award for evidence-based public health achievement. The annual award, sponsored by IHME's founding board member David Roux and his wife, Barbara, recognizes people worldwide for their innovative and impactful use of IHME's Global Burden of Disease data.

Key Points: 
  • SEATTLE, July 22, 2022 /PRNewswire/ -- The Institute for Health Metrics and Evaluation (IHME) at the University of Washington today announced Mukteshwari "Mukti" Bosco, CEO and Founder of Healing Fields Foundation , is the recipient of the 2022 Roux Prize, the world's largest award for evidence-based public health achievement.
  • "The Roux Prize recognizes creative problem-solvers like Mukti who are the driving force behind real change.
  • Her determination to overcome daunting barriers and turn evidence into action exemplifies the spirit of the Roux Prize."
  • "Receiving the Roux Prize reflects the transformative power of our Community Health Entrepreneurs, their communities, and the entire Healing Fields organization," said Bosco.

The Lancet: Disparities in life expectancy persist among racial and ethnic groups across the US

Retrieved on: 
Friday, June 17, 2022
American Indians, Article, Time, National Center for Health Statistics, Population, NVSS, Centers for Disease Control and Prevention timeline, Mortality, Smoking, COVID-19, Obesity, Alaska Natives, Academy of Medical Sciences (United Kingdom), 2009 Davis Cup, National Institute on Minority Health and Health Disparities, Map, Death, Institute for Health Metrics and Evaluation, Feedback, Institute, Life expectancy, University Place, Washington, Data visualization, Research, NCHS, API, Manuscript, National Vital Statistics System, Hypertension, University, Policy, Health, Sex, IHME, Medical statistics, Communication, Academy, Medicine, Multimedia, American, Diabetes, Use-centered design, Risk, Tutoring, Road, Pharmaceutical industry, Medical device, Oil, Lancet, Evaluation, AIAN, Black, White

New study offers the first comprehensive, county-level life expectancy estimates in the US and highlights important differences among racial and ethnic groups.

Key Points: 
  • New study offers the first comprehensive, county-level life expectancy estimates in the US and highlights important differences among racial and ethnic groups.
  • The analysis reveals that despite overall life expectancy gains of 2.3 years (from 76.8 years in 2000 to 79.1 years in 2019) during the 20-year study period (20002019), disparities among racial and ethnic groups remain, with Black populations still experiencing shorter life expectancy than White populations.
  • "Gains in life expectancy are noteworthy but stop short of suggesting we're closing the gap that persists among different racial and ethnic groups.
  • The study's results highlight considerable variation in life expectancy among racial and ethnic groups, locations, and over time, exposing both positive and negative trends.